Home > Press > NanoImaging Services Relocates to Larger Facility in La Jolla, Calif.
Abstract:
Biopharmaceutical analytical services company expands into a 2,500 square-foot laboratory and adds staff to accommodate growing business
NanoImaging Services, Inc., the leading provider of high-resolution, three-dimensional (3D) transmission electron microscope (TEM) imaging services to manufacturers of large molecule biopharmaceuticals, announced today that it has moved to a larger facility in La Jolla, Calif. The new 2,500-square-foot facility will enable NanoImaging Services to expand the capacity of its service laboratory and add new employees in an effort to accommodate its growing biopharmaceutical client base.
"By allowing researchers to actually see the nano scale structures they are working with, we help them improve speed and reduce risk in all phases of the drug development process, from discovery and characterization through approval and manufacturing," said Clint Potter, CEO, NanoImaging Services. "This new facility will allow us to meet the rapidly growing demand we have seen already in our first four months of operation."
NanoImaging benefited from early support and funding from Merck Capital Ventures, LLC, a subsidiary of Merck & Co., Inc., and FEI Company. The company's new location is 10931 North Torrey Pines Road, # 108, San Diego, CA 92037 USA. For more information, please visit www.nanoimagingservices.com.
####
About NanoImaging Services, Inc.
NanoImaging Services, Inc. provides transmission electron microscope imaging services to the pharmaceutical, biotechnology and nanotechnology industries, and specializes in the characterization of large biological molecules used in biopharmaceuticals such as vaccines, antibodies, cytokines, hormones and gene therapies. In contrast to conventional (small molecule) drugs, biopharmaceuticals are typically protein-based and manufactured in controlled, modified, biological systems. Their complexity and similarity to naturally occurring compounds makes a detailed understanding of their structure, and its relationship to their safety and efficacy, essential in their development and approval. Biopharmaceuticals represent an important and rapidly-growing segment of the pharmaceutical industry.
For more information, please click here
Contacts:
Clint Potter
NanoImaging Services, Inc.
888-675-8261
Sandy Fewkes
MindWrite Communications, Inc.
408-224-4024
Copyright © NanoImaging Services, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Imaging
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Openings/New facilities/Groundbreaking/Expansion
OCSiAl expands its graphene nanotube production capacities to Europe June 17th, 2022
GLOBALFOUNDRIES Moves Corporate Headquarters to its Most Advanced Semiconductor Manufacturing Facility in New York April 27th, 2021
Oxford Instruments Plasma Technology relocates to advanced manufacturing facility: Move driven by exceptional business growth February 12th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||